2 Final-Studien (Brust & Leberkrebs) Mkap 35 M$

wohin die Reise geht  

 

mit etwas Fantasie könnten die nächsten Tage 200% drinnen sein ;-))  

http://video.cnbc.com/gallery/?play=1&video=3000172054  

http://finance.yahoo.com/q?s=CLSN  

 

LAWRENCEVILLE, N.J., Jan. 31, 2013 /PRNewswire/

 

hauptsache das Teil geht nach Norden.
Pre-Market : 1.91 Up 0.15 (8.52%) 9:23AM EDT - Nasdaq Real Time Price  

 

Na Leute,wer behält hier Recht am Ende,hm ?  

 

Celsion Corporation Announces $9.83 Million Registered Direct Offering16:05 31.05.13


PR Newswire

LAWRENCEVILLE, N.J., May 31, 2013

LAWRENCEVILLE, N.J., May 31, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ:CLSN) (the "Company") today announced that it has received commitments from institutional investors to purchase an aggregate of approximately $9.83 million of the Company's common stock in an at-the-market registered direct offering led by a dedicated health care fund.

The Company entered into definitive purchase agreements with these investors pursuant to which the Company agreed to sell an aggregate of 6,264,492 shares of its common stock at a per share price of $1.57.  The shares were priced at-the-market with no discount to the previous day's closing bid price.  In addition, there were no warrants issued as part of this financing transaction.  The closing of the offering is expected to take place on or about June 4, 2013, subject to the satisfaction of customary closing conditions.

The estimated net proceeds to the Company from the offering are expected to be approximately $9.1 million.  With the net proceeds from this offering, the Company projects to have an unaudited cash and investment balance of approximately $50 million.  The Company intends to use the net proceeds from this offering for general corporate purposes.

H.C. Wainwright & Co., LLC  acted as exclusive placement agent in connection with the offering.

A shelf registration statement (File No. 333-183286) relating to the shares issued in the offering has been filed with and declared effective by the Securities and Exchange Commission (the "SEC").  A prospectus supplement relating to the offering will be filed by the Company with the SEC.  Copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC's website at http://www.sec.gov, from request at H.C. Wainwright & Co., LLC by e-mailing placements@hcwco.com, or from Celsion Corporation, 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648, Attention: Investor Relations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company in this offering. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.  Any offering will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.  

Additional Information:

Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, but not limited to, the amount and use of proceeds the Company expects to receive from the offering and the closing of the offering. Forward-looking statements can be identified by the use of words such as "may," "will," "plan," "should," "expect," "project," "anticipate," "estimate," "continue," or comparable terminology. Such forward-looking statements are inherently subject to certain risks, trends and uncertainties, many of which the Company cannot predict with accuracy and some of which the Company might not even anticipate, and involve factors that may cause actual results to differ materially from those projected or suggested. Readers are cautioned not to place undue reliance on these forward-looking statements and are advised to consider the factors listed above together with the additional factors under the heading "Forward-Looking Statements" and "Risk Factors" in the Company's Annual Reports on Form 10-K, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact

Jeffrey W. Church

Senior Vice President – Corporate

Strategy and Investor Relations

609-482-2455

jchurch@celsion.com  

SOURCE Celsion Corporation  

Es geht doch hier nicht darum ob wer auch immer Recht hat , allerdings sollte nach der News von Heute doch erst einmal die Unsicherheit ein wenig rausgehen.

15 Millionen $ am Markt plaziert mit einem Aufschlag von 50% auf den Kurs von letzter Woche.
Marktkap. ist fast gleich Cashbestand von 50 Mio $ ( auch wenn "unaudited" )

Ich habe gestern mein Shares bei 2$ zur Hälfte rausgehauen ( der Rest Gewinn blieb drin , und habe bei 1,60 $ wieder aufgestockt ;)

Gruß

ttH  

die Meldung zu verstehen.

Hat Celsion eigene Aktien aus eigenem Bestand verkauft oder wurden junge Aktien ausgegeben?

Für Antworten schon mal danke.  

sehr hohe Umsätze wieder  

glückwunsch zu 1000% bei Thomas cook !! Willst du deine Gewinne mit Celsion wieder verlieren ???  

bin ich ja schon wieder raus...  

http://www.hotstocked.com/article/54922/...-clsn-tries-to-regain.html  

nachbörslich er Ausverkauf  

http://seekingalpha.com/article/...he-heat-trial-failed?source=nasdaq

War es das?  

http://www.nasdaq.com/symbol/clsn/after-hours  

mal sehen wo der kurs sich heute anpendelt...

das problem ist das eine neue studie

1. nochmal viel geld kosten würde und
2. sehr viel zeit in anspruch nehmen könnte. lt. medienberichten sind 4-5 Jahre im gespräch

hat celsion noch etwas anderes in der pipe?  

Aber mir glaubt man offenbar nicht,hm rudini ? Jetzt habta die Kacke am dampfen ! Wenn ihr denselben Wahnsinn nochmal wiederholen wollt,dann empfehle ich den FDA (nicht-) Zulassungszock von Enteromedics mitzunehmen,die aktie steht bei 1,15 dollar,die Amis wollen aber 15 Dollar sehen ,kein witz ! Und das beste ist,das ist keine Einfache Fett-Weg Pille,sondern ein batteriebetriebenes implantiertes Elektrodensystem gegen Fettleibigkeit ! Ich halte das alles für einen schlechten witz,aber der Antrag ist bereits gestellt und man kennt ja die Amis ......

MFG
Chali  

Ein Artikel ist erschienen, der sich kritisch mit Celsion beschäftigt. Das der Test fehlgeschlagen ist war auch schon vor Tagen bei dem Hype bekannt. Es gibt unterschiedliche Meinungen zur Bewertung der Daten.Alles in allem nix neues.

Ich rechne damit, das zum Handelsstart in den USA sich vieles wieder gerade biegen wird.
Werde meine Stücke bis zur Veranstaltung in Italien behalten.

Wir besitzen eine sehr spannende Aktie.